BRD1 bromodomain (556-680 aa) (GST-tagged), human recombinant protein
Human recombinant BRD1 bromodomain (556-680 aa) (GST-tagged)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O95696 |
---|---|
Calculated MW | 41.1 kDa (556-680 aa + NT GST Tag) |
Gene ID | 23774 |
---|---|
Gene Symbol | BRD1 |
Other Names | Bromodomain containing 1, DKFZp686F0325, BR140-like protein, BRL, BRPF1, BRPF2, Bromodomain and PHD finger-containing protein 2 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥95% |
Assay2&Purity2 | N/A; |
Recombinant | Yes |
Target/Specificity | BRD1 |
Format | Liquid |
Storage | -80°C; 50 mM Tris, pH 7.5, containing 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as “readers” of histone acetylation marks regulating the transcription of target promoters. BRD1 is a bromodomain containing protein that has been identified as a susceptibility gene in neurological disorders, such as schizophrenia and bipolar affective disorder. This protein can be used for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.
References
McCullagh P.,et al.Oncogene 18:7442-7452(1999).
Collins J.E.,et al.Genome Biol. 5:R84.1-R84.11(2004).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Dunham I.,et al.Nature 402:489-495(1999).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.